Page 140 - 2020_02-Haematologica-web

G. Greiner et al.
Mastocytosis. Clin Chem. 2018;64(3):547-
555.
17. Erben P, Schwaab J, Metzgeroth G, et al. The
KIT D816V expressed allele burden for diag- nosis and disease monitoring of systemic mastocytosis. Ann Hematol. 2014;93(1):81- 88.
18. Hoermann G, Gleixner KV, Dinu GE, et al. The KIT D816V allele burden predicts sur- vival in patients with mastocytosis and cor- relates with the WHO type of the disease. Allergy. 2014;69(6):810-813.
19. Jara-Acevedo M, Teodosio C, Sanchez- Munoz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138-1149.
20. Broesby-Olsen S, Kristensen T, Vestergaard H, et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol. 2013;132(3):723-728.
21. Mayado A, Teodosio C, Dasilva-Freire N, et al. Characterization of CD34(+) hematopoi- etic cells in systemic mastocytosis: Potential role in disease dissemination. Allergy. 2018; 73(6):1294-1304.
22. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol. 1985;16(8):808-814.
23. Krokowski M, Sotlar K, Krauth MT, Fodinger M, Valent P, Horny HP. Delineation of patterns of bone marrow mast cell infil- tration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. Am J Clin Pathol. 2005;124(4): 560-568.
24. Jawhar M, Schwaab J, Naumann N, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137-145.
25. Development Core Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2005.
26. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoiet- ic cell lineages in systemic mast cell disor- ders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7): 2366-2372.
27. Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage relation- ship between mast cells and basophils using the c-kit D816V mutation as a biologic sig- nature. J Allergy Clin Immunol. 2005;115(6):1155-1161.
28. Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, et al. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associat- ed with disease progression. Blood. 2016;127(6):761-768.
29. Pardanani A, Lim KH, Lasho TL, et al. WHO subvariants of indolent mastocytosis: clini- cal details and prognostic evaluation in 159 consecutive adults. Blood. 2010;115(1):150- 151.
30. Ustun C, Arock M, Kluin-Nelemans HC, et al. Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. Haematologica. 2016;101(10):1133- 1143.
31. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016;374(26):2530-2541.
32. Bibi S, Arock M. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT. Immunol Allergy Clin North Am. 2018;38(3):527-543.
33. Lortholary O, Chandesris MO, Bulai Livideanu C, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-con- trolled, phase 3 study. Lancet. 2017; 389(10069):612-620.
34. van Anrooij B, Oude Elberink JNG, Span LF, et al. Midostaurin in indolent systemic mas- tocytosis patients: an open-label phase 2 trial. J Allergy Clin Immunol. 2018; 142(3):1006-1008.
35. DeAngelo DJ, Quiery AT, Radia D, et al. Clinical Activity in a Phase 1 Study of Blu- 285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM). Blood. 2017;130 (Suppl 1):2-2.
36. Jawhar M, Schwaab J, Hausmann D, et al. Splenomegaly, elevated alkaline phos- phatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016;30(12):2342-2350.
37. Jawhar M, Schwaab J, Schnittger S, et al.
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced sys- temic mastocytosis. Leukemia. 2016; 30(1):136-143.
38. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003; 27(7):635-641.
39. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocyto- sis: correlation with mast cell burden and implication for defining the category of dis- ease. Int Arch Allergy Immunol. 2002;128 (2):136-141.
40. Kabashima K, Nakashima C, Nonomura Y, et al. Biomarkers for evaluation of mast cell and basophil activation. Immunol Rev. 2018;282(1):114-120.
41. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015;373(2):163-172.
42. Valent P, Sperr WR, Sotlar K, et al. The serum tryptase test: an emerging robust bio- marker in clinical hematology. Expert Rev Hematol. 2014;7(5):683-690.
43. Jawhar M, Schwaab J, Horny HP, et al. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest. 2016;46(5):392-397.
44. Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a dis- tinct and late event. Leukemia. 2015;29(5):1115-1122.
45. Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Moller MB. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis. Eur J Haematol. 2016;96(4): 381-388.
46. Kristensen T, Vestergaard H, Bindslev-Jensen C, et al. Prospective evaluation of the diag- nostic value of sensitive KIT D816V muta- tion analysis of blood in adults with suspect- ed systemic mastocytosis. Allergy. 2017;72(11):1737-1743.
47. Broesby-Olsen S, Oropeza AR, Bindslev- Jensen C, et al. Recognizing mastocytosis in patients with anaphylaxis: value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol. 2015;135(1): 262-264.
374
haematologica | 2020; 105(2)